Total Voting Rights

(AIM : SAR)

29 November 2013

Sareum Holdings plc
("Sareum" or "the Company")

Total Voting Rights

The Company announces that, pursuant to the requirements of the Disclosure and Transparency Rules, the total number of voting rights in respect of each class of share in issue and admitted to trading on AIM at the date of this announcement is as follows:

	Total number of shares in issue	Total number of voting rights
Ordinary Shares of 0.025 pence each	1,800,038,273	1,800,038,273

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

For further information:
Sareum Holdings plc Tim Mitchell	01223 497 700
Sanlam Securities UK Limited (Nomad) Simon Clements	020 7628 2200
Hybridan LLP (Broker) Claire Noyce / William Lynne	020 7947 4350 / 4361
The Communications Portfolio Limited (Media enquiries) Ariane Comstive [e-mail]	020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licencing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, TYK2 and VEGFR-3 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SAREUM HOLDINGS PLC via Globenewswire

HUG#1746626